Risk Partners Life Sciences Roundtable 2025, thank you very much!ย 

Contact us

๐—š๐—น๐—ผ๐—ฏ๐—ฎ๐—น ๐—œ๐—ป๐˜๐—ฒ๐—ด๐—ฟ๐—ถ๐˜๐˜† ๐—ฎ๐—ป๐—ฑ ๐—–๐—ผ๐—บ๐—ฝ๐—น๐—ถ๐—ฎ๐—ป๐—ฐ๐—ฒ ๐—™๐—ผ๐—ฟ๐˜‚๐—บ ๐Ÿฎ๐Ÿฌ๐Ÿฎ๐Ÿฐ

"D&O and Co. - Plan B to cover personal liability!"

Last Friday, Florian had the honor of attending the Global Integrity and Compliance Forum at the Ludwig-Maximilians-Universitรคt in Munich. Under the motto "The RULE of LAW in the Era of Integrity & Compliance", international legal experts, company managers, in-house councils and compliance officers from all over the world gathered to discuss the future of good corporate governance in 2024.

Key discussions and findings One of the main topics was the liability of company executives and members of the supervisory board, which underscored the growing importance of a comprehensive risk management strategy. It became clear that an effective compliance management system today must not only be in place but also documented and traceable. Florian led an important session on the topic โ€œD&O and Co. โ€“ Plan B to Cover Personal Liability,โ€ in which he demonstrated how executive board and supervisory board members can protect themselves from liability through personal risk management. Here are some of the key points:

1. contractual agreements:
  • Indemnification and procurement clauses in the secondment or mandate agreement
  • Overview and assurances from the company's D&O insurance

2. tool-based approaches:
  • Use of corporate governance tools, such as Fides
  • Compliance with the Business Judgement Rule and documentation of concerns of the Supervisory Board to mitigate personal liability

3. D&O protection:
  • Regular due diligence of the corporate D&O
  • Examination of supplementary private provision (personal D&O, top manager legal protection, etc.)

Thanks and outlook

Special thanks to Alexander Schemmel, the Boston Consulting Group (BCG) and the GCE Counsellors at Law team for the invitation and the opportunity to participate in this inspiring event. The exchange with the experts and the discussions in the LMU premises were extremely enriching.

Are you a member of the executive board, managing director or supervisory board yourself? Let's discuss, without obligation, how our special concepts of software solutions and D&O insurance can protect you and offer best practices for personal protection in a modern management environment. Together we can further improve corporate governance and ensure greater integrity and compliance in the business world. We look forward to hearing from you!

Also read our other blog posts
Being Public

"I believe in a strong IPO comeback in 2024" - Interview Platform Life Sciences

Risk Partners in the trade press. Florian was approached by the journalists from Plattform Life Sciences for an interview on our view of 2024 and the development of Risk Partners over the past year. In addition to challenging claims, product innovations (e.g. all about POSI insurance) from Risk Partners, Florian also discusses our motives for the "team up" with the fantastic colleagues from Atrialis GmbH - experts in clinical trials. Click here for Florian's interview. Read the interview

Read more "
January 11, 2024
Life Sciences

St. Gallen study: USD 6 billion per drug

HSG St. Gallen: Drug costs USD 6.16 billion on average. Are the days of new drugs costing less than USD 1 billion over? There were figures in the industry that spoke of USD 700-1,000 million as the cost of developing a new drug. A study by the University of St. Gallen covering the period 2001-2020 found that the cost of developing new drugs has risen dramatically. It was estimated that the cost of developing a new drug now stands at

Read more "
September 26, 2023
4 pillars of cyber insurance for venture capital and private equity
Cyber Security

Cyber insurance Venture capital and private equity

Why cyber insurance does not transfer the core risk of VC & PE funds and why we have invested in Risk Partners cyber master agreements. Why cyber risks are relevant for venture capital and private equity funds With the increasing growth of the cyber crime industry (see Federal Office for the Protection of the Constitution), venture capital (VC) and private equity (PE) funds and their fund managers are also increasingly exposed to cyber risks. For years, this has been reflected in the claims we have been able to support, in which fund managers have ranked first year after year among the industries we advise.

Read more "
December 29, 2024
Life Sciences

Finance Day 2024

Growth capital for biotechnology and life sciences - Finance Day 2024 A few days ago, Jutta and Florian from our team attended Finance Day 2024 at the analytica trade fair in Munich. The event once again offered exciting expert panels on current financing and capital market issues for life sciences companies. As the panels focused on three of our key consulting areas, namely life sciences, venture capital and IPOs, attending was of course a must for us as a specialist insurance broker. Our team was also very pleased to meet many of our partners and clients again.

Read more "
April 19, 2024
IPO

New: Risk Partners POSI Insurance for MiCAR White Paper

MiCAR Compliance? We Cover the Risk! The MiCAR Regulation (EU 2023/1114) exposes crypto-asset service providers and whitepaper authors to significant liability risks. Incomplete, inaccurate, or misleading information in white papers can have significant consequences for Crypto-Asset Service Providers (CASP) and authorsโ€”ranging from regulatory sanctions to civil claims. Our solution: Risk Partners Tech POSI MiCAR Whitepaper Protect 2025 The creation and publication of white papers under MiCAR entails complex liability pitfalls: In addition to civil claims (e.g., under the German Civil Code) and criminal risks, there is a threat of

Read more "
March 21, 2026
Life Sciences

Finance Day 2023

Growth capital for biotechnology: Yesterday, today, tomorrow! A few days ago, Jutta Zaglauer and Florian Eckstein from our team attended the Finance Day 2023 on the occasion of the 25th anniversary of biotechnology at the IZB - Innovation and Startup Center for Biotechnology. The event offered an exciting exchange and insights into current financing and capital market issues of biotechnology companies. As an experienced specialist insurance broker for the areas of life sciences, venture capital and IPOs, all three cornerstones of our "magic expertise triangle" were part of the exciting agenda. It was also interesting to discuss the importance of customized

Read more "
November 6, 2023